Influenza Diagnostics Market Size, Share, and Analysis, By Technology (Nucleic Acid Amplification {Reverse Transcription Polymerase Chain Reaction (RT-PCR), and Isothermal Amplification}, Lateral Flow Assay, Immunofluorescence Assays, and Others), By Product (Kits & Reagents, and Instruments), By End-User (Clinical Laboratories, Hospitals & Clinics, and Others), and Regional Forecast, 2024-2032

Influenza, also known as flu, is an infectious disease caused by an influenza virus. Diagnosis of the influenza virus is possible through conventional and modern methods using different diagnostic techniques. Influenza Diagnostics include viral culture, serology, rapid antigen testing, reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence, and rapid molecular assays. Increasing prevalence of chronic ailments such as lung disease, and others is leading to the increased influenza infection rate among the patient population.

• For instance, in 2021, according to American Lung Association it is reported that nearly 37 million Americans live with a chronic lung disease such as asthma, COPD, and others. The patients suffering from lung diseases and others are more prone to influenza flu.


• In 2021, according to the Centers for Disease Control & Prevention (CDC), 9 million patients were affected with Influenza.

Additionally, the growing geriatric population is accelerating the chances of higher rates of influenza flu among the population. According to an analysis by World Health Organization, the elderly population is at higher risk of getting infected from influenza flu and therefore must be vaccinated first to prevent the fast spread of influenza flu.

• In September 2022, according to U.S. Census Bureau, it is reported that there are more than 54 million adults aged 65 or older in the U.S. Thus, this increasing elderly population are more prone to the infection of influenza flu.  

Moreover, increasing prevalence of influenza flu has also shifted the key players’ focus on the advancement of these influenza diagnostic kits, contributing to the rising adoption and growth of the market. Thus, the key players have started focusing on the introduction of advanced rapid antigen kits that quickly differentiates between SARS COV-2 and Influenza A and B viruses.

• In December 2021, Roche launched SARS COV-2 & Flu A/B rapid antigen test that quickly differentiates between SARS COV-2 and Influenza A and B viruses. Thus, growing prevalence of influenza along with the rising demand for influenza diagnostics tests is augmented to the growth of the market.

Impact of COVID-19 on Influenza Diagnostics Market 

The COVID-19 pandemic has negatively impacted the influenza diagnostics market. COVID-19 has severely impacted the market across the world due to the disruption of supply chain, inadequate funding to research and academic institutions, and others.

On the other hand, due to large similarities in COVID-19 and influenza flu such as seasonal flu, contagious nature and same occurrence, many clinicians prescribed COVID-19 test instead of influenza flu and that led to the decreased diagnosis of influenza test during the pandemic.

• For instance, according to data published on Centers for Disease Control & Prevention (CDC), it is reported that data from clinical laboratories in the U.S. experienced a 61% decrease in the number of specimens submitted for influenza test from September 2019 to February 2020.

Key Insights: 

• Prevalence of Influenza, Key Countries/ Regions, 2021


• Pricing Analysis, By Key Players, 2021


• Key Industry Developments- Partnerships, Mergers, and Acquisitions


• Impact of COVID-19 on Influenza Diagnostics Market

Analysis by Test Type:

Based on the test type, the market is bifurcated into molecular assays, antigen detection tests and others. Amongst these, the antigen detection tests holds the dominant position in the market due to increasing diagnosis for influenza among patient population. Moreover, the rapid influenza diagnostic test consumes less time and are cost-effective leading to their increased adoption among the patient population. This, along with increasing FDA approvals for the rapid influenza diagnostic tests is also leading to the growth of the segment in the market.

On the other hand, molecular assays is anticipated to register a significant CAGR. This is attributed to key players focusing on the advancement in reverse transcription PCR. Also, the advantage of RT-PCR technique to distinguish between different strains of influenza virus and between influenza virus and COVID-19 is leading to the growth of the segment in the market. The growth is also due to the rising demand for influenza testing kits owing to the increasing prevalence of influenza worldwide

Regional Analysis: 

North America market holds the largest share in the market due to increased government initiatives to support the adoption of influenza diagnostic tests among the patient population. Additionally the increasing prevalence of influenza is leading to the increasing demand for influenza diagnostic tests. This is further increasing the adoption of these advanced kits among the patient population. This huge demand and adoption is enabling the key players to invest in research and development activities with an aim to meet the demand supply gap and supporting the growth of the market.

On the other hand, Asia Pacific is anticipated to register a significant CAGR. This is attributed to the rising inorganic strategies such as collaborations and mergers among the major key players to expand the influenza test portfolio in the Asia Pacific market. This along with development in healthcare infrastructure and rising initiatives for the awareness regarding the influenza disease have been instrumental for the growing adoption of diagnostics devices in this region.

Key Players: 

The report will include the profiles of key players such as Abbott, F. Hoffmann-La Roche Ltd, BD, bioMérieux SA, Quidel Corporation, Sekisui Diagnostics, GenMark Diagnostics, Inc., and Meridian Bioscience, Hologic, Inc.

Segmentation: 

Key Industry Developments:

• In September 2021, DiaSorin Molecular announced the CE mark approval for Simplexa COVID-19 & Flu A/B Direct kit, which allows  in-vitro qualitative detection and differentiation of nucleic acid from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus and influenza B virus.


• In May 2021, BD announced FDA approval on the BD Veritor Plus System for the detection of SARS COV-2, Influenza A and Influenza B in case of emergency.


• In March 2021, Abbott announced USFDA emergency use approval for Alinity m Resp 4-Plex molecular assay with an aim to detect and differentiate between SARS COV-2, Influenza A and Influenza B.